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Due to the rapidly increasing prevalence of multidrug-resistant bacterial strains, the need
for new antimicrobial drugs to treat infections has become urgent. Bacteriocins, which
are antimicrobial peptides of bacterial origin, are considered potential alternatives to
conventional antibiotics and have attracted widespread attention in recent years. Among
these bacteriocins, lantibiotics, especially two-component lantibiotics, exhibit potent
antimicrobial activity against some clinically relevant Gram-positive pathogens and have
potential applications in the pharmaceutical industry. In this study, we characterized a
novel two-component lantibiotic termed thusin that consists of Thsα, Thsβ, and Thsβ’
(mutation of Thsβ, A14G) and that was isolated from a B. thuringiensis strain BGSC
4BT1. Thsα and Thsβ (or Thsβ’) exhibit optimal antimicrobial activity at a 1:1 ratio and act
sequentially to affect target cells, and they are all highly thermostable (100◦C for 30min)
and pH tolerant (pH 2.0 to 9.0). Thusin shows remarkable efficacy against all tested
Gram-positive bacteria and greater activities than two known lantibiotics thuricin 4A-4
and ticin A4, and one antibiotic vancomycin against various bacterial pathogens (Bacillus
cereus, Listeria monocytogenes, Staphylococcus aureus (MRSA), Staphylococcus
sciuri, Enterococcus faecalis, and Streptococcus pneumoniae). Moreover, thusin is also
able to inhibit the outgrowth ofB. cereus spores. The potent antimicrobial activity of thusin
against someGram-positive pathogens indicates that it has potential for the development
of new drugs.
Keywords: two-peptide lantibiotics, Bacillus thuringiensis BGSC 4BT1, thusin, vancomycin, Gram-positive
pathogens
INTRODUCTION
The introduction of antibiotics for the treatment of infections is the most significant scientific
achievement of the twentieth century with regard to reducing human morbidity and mortality
(Andersson and Hughes, 2010; Brown and Wright, 2016). Unfortunately, the extensive use of
antibiotics has resulted in the development of multidrug-resistant pathogens, and mining new
antimicrobials is considered to be an effective solution to this problem (Cotter et al., 2013).
To date, the investigated alternatives to traditional antibiotics include plant-derived compounds,
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bacteriophages, RNA-based therapeutics, probiotics, and
antimicrobial peptides of different origins (Shanahan, 2010;
Burrowes et al., 2011; Kole et al., 2012; Li et al., 2012; Savoia,
2012). Antimicrobial peptides of bacterial origin, known as
bacteriocins, are ribosomally synthesized peptides that exert a
bactericidal or bacteriostatic effect on other bacteria either of
the same species (narrow spectrum) or across genera (broad
spectrum) and have been regarded as a promising source
of antimicrobials (Cotter et al., 2005, 2013). They include
posttranslationally modified bacteriocins and unmodified or
cyclic bacteriocins (Cotter et al., 2013).
Lanthipeptides (lantibiotics) are small peptides that undergo
extensive posttranslational modification and are considered
the best-characterized bacteriocins (Schnell et al., 1988; Willey
and Van der Donk, 2007). The posttranslational modifications
include the dehydration of Ser and Thr residues to yield
dehydroalanine (Dha) and dehydrobutyrine (Dhb) residues,
respectively. This dehydration is followed by the stereospecific
intramolecular addition of a Cys residue onto the dehydroamino
acids to form a lanthionine (Lan) or methyllanthionine (MeLan)
bridge. Many lantibiotics exhibit broad-spectrum antimicrobial
activity against clinically relevant Gram-positive pathogens,
including multidrug-resistant pathogens, and are a promising
class of new antibacterial agents (Severina et al., 1998; Cotter
et al., 2005, 2013; Dischinger et al., 2014; Sandiford, 2014).
A special subclass of two-component lantibiotics consists
of two peptide systems that are formed from two precursor
peptides posttranslationally modified to form two distinct
active products (Garneau et al., 2002). The individual peptides
have little or no antimicrobial activity; however, equimolar
concentrations of the two peptides act in synergy to exhibit
significantly higher activity (Morgan et al., 2005). At present,
a number of two-component lantibiotics have been described,
some of which may have applications in the pharmaceutical and
food industries (Navaratna et al., 1998; Ryan et al., 1999; Holo
et al., 2001; Hyink et al., 2005; Yonezawa and Kuramitsu, 2005;
McClerren et al., 2006; Begley et al., 2009; Sawa et al., 2012). For
example, the best-studied two-component lantibiotic, lacticin
3147, consists of Ltnα and Ltnβ and exhibits potent antimicrobial
activity against a number of pathogenic Gram-positive bacteria,
such as methicillin-resistant Staphylococcus aureus (MRSA),
vancomycin-resistant Enterococcus faecalis (VRE), penicillin-
resistant Pneumococcus (PRP), Propionibacterium acnes,
Streptococcus mutans, Clostridium difficile, and Mycobacteria
(Galvin et al., 1999; Morgan et al., 2005; Rea et al., 2007; Carroll
et al., 2010; Dobson et al., 2011; Piper et al., 2012). Lacticin 3147
also substantially attenuated Strep. mutans biofilm formation
(Dobson et al., 2011) and prevented the systemic spread of
Staph. aureus in mice (Piper et al., 2012). Although there are
a number of two-component lantibiotics have been described,
the properties of them are different, such as the antimicrobial
activity and stability (Willey and Van der Donk, 2007; Knerr
and Van der Donk, 2012). Therefore, it’s necessary to mine more
antimicrobials of that type to satisfy people’s demands.
In our previous research, we demonstrated that the B. cereus
group is an excellent reservoir of novel lanthipeptides, and
four types of two-component lanthipeptide gene clusters
were predicted in the strains of this group (Xin et al.,
2015b). In this study, we identified and characterized
one type of the two-component lantibiotics, the thusin
gene cluster from a B. thuringiensis strain BGSC 4BT1.
The two components, Thsα and Thsβ (or Thsβ’), acted
synergistically against most of the tested Gram-positive
bacteria and were able to inhibit the outgrowth of Bacillus
cereus spores. In addition, comparison of the antimicrobial
activities of thusin, thuricin 4A-4, ticin A4, and vancomycin
against six species of Gram-positive bacterial pathogens
suggested that thusin may be a promising therapeutic
agent.
MATERIALS AND METHODS
Strains and Culture Conditions
The B. thuringiensis strain BGSC 4BT1 was kindly provided by
the Bacillus Genetic Stock Center (BGSC) and propagated on
TABLE 1 | The antimicrobial activity of Thsα, Thsβ, and Thusin.
Indicator straina MIC (µM)b
Thsα Thsβ Thusin
GRAM-NEGATIVE BACTERIA
Sphingobacterium Pri1 – – –
Pseudomonas putida Pri3 – – –
Pseudomonas psychrophila Pri5 – – –
Escherichia coli OP50 (Xin et al., 2015a) – – –
E. coli BL21 (Xin et al., 2015a) – – –
Erwinia herbicola LS005(Xin et al., 2015a) – – –
Klebsiella pneumoniae CMCC 46117 – – –
Salmonella paratyphi CMCC 50093 – – –
Salmonella paratyphi CMCC 50094 – – –
Shigella dysenteriae CMCC 51105 – – –
Pseudomonas aeruginosa ATCC 27853 – – –
GRAM-POSITIVE BACTERIA
Bacillus cereus ATCC 14579 6.25 12.5 0.78
Bacillus thuringiensis BMB171 (Xin et al., 2015a) 6.25 6.25 0.39
Bacillus pumilus SCG I (Xin et al., 2015a) 6.25 12,5 0.39
Bacillus subtilis Bsn5 (Deng et al., 2011) 6.25 12.5 0.78
Bacillus amyloliquefaciens X1 (Xin et al., 2015a) 12.5 12.5 1.56
Listeria monocytogenes LM201 (Wu et al., 2015) 6.25 12.5 0.78
Listeria monocytogenes LM605 12.5 12.5 0.78
Staphylococcus aureus CMCC 26003 25.0 25 1.56
Staphylococcus aureus ATCC 43300 12.5 25.0 1.56
Staphylococcus aureus MRSA 25.0 25.0 1.56
Staphylococcus sciuri Bom1 12.5 12.5 0.78
Enterococcus faecalis ATCC 29212 50.0 50.0 3.13
Streptococcus pneumoniae ATCC 49619 6.25 12.5 1.56
aATCC, American Type Culture Collection. CMCC, China Medical Culture Collection. See
references for the source of the marked strains. Unmarked strains were isolated by our
group.
bThe highest concentrations of Thsα, Thsβ, and Thusin were all 100µM. The minus sign
denotes no activity against the indicator strains, even at the highest concentrations of the
indicated peptides.
Frontiers in Microbiology | www.frontiersin.org 2 July 2016 | Volume 7 | Article 1115
Xin et al. A Novel Two-Component Lantibiotic Thusin
Luria-Bertani (LB) agar plates at 28◦C. The other strains, which
served as indicator strains, are listed in Table 1.
The Prediction of the Lanthipeptide
Biosynthetic Gene Cluster and Analysis of
the Promoter and Terminator in the Thusin
Gene Cluster
The bacteriocin biosynthetic gene clusters were predicted using
BAGEL 3.0 (Van Heel et al., 2013). The putative promoter
and terminator in the thusin gene cluster were detected using
the Softberry BPROM and Find Term software programs,
respectively.
Purification of Antibacterial Peptides
B. thuringiensis BGSC 4BT1 was grown in Luria-Bertani (LB)
broth at 28◦C. At the early stationary phase (OD600≈3.0), the
cells were removed by centrifugation at 12,000 rpm for 10min.
The concentration of active substances was measured using
FIGURE 1 | Thusin biosynthetic gene cluster in B. thuringiensis BGSC 4BT1 and amino acid sequence alignment of three precursor peptides with
class II lantibiotic propeptides. (A) Line diagram of the thusin gene cluster in B. thuringiensis BGSC 4BT1. Bent arrow represents the promoter of the thusin gene
cluster. Amino acid sequence alignment of ThsA1 (B), ThsA2 and ThsA2′ (C) with other reported class II lantibiotic propeptides. Cys residues are marked in red.
Ser/Thr residues that are dehydrated are shown in blue, and non-dehydrated residues are underlined. Ser/Thr residues, post-translationally modified to D-Ala/Obu,
are shown in green/yellow. Thioether and disulfide bonds are marked with arrows and are boxed in gray. Two of the six Ser/Thr residues are not dehydrated in the
mature peptides of ThsA2 and ThsA2′, but these residues could not be conclusively identified based on the current data; these six amino acids are displayed in violet.
Thioether bridging rings in the Lchα and Lchβ peptides are indicated with the capital letters A, B, C, and D. The probable protease cleavage site sequences (GG) are
shown in red.
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Amberlite XAD-7HP (Sigma, St Louis, MO, USA) as described
previously (Xin et al., 2015a). Briefly, the cell-free supernatant
fluid (5 L) was shaken with 500 g of Amberlite XAD-7HP (Sigma,
St. Louis, MO, USA) for 12 h at 4◦C. The resin was sequentially
washed with 2 L of distilled water and 1 L of 30% (vol/vol)
ethanol. The active substances were eluted with 500mL of 80%
(vol/vol) ethanol, pH 2.0, and the eluate was collected and
lyophilized into a powder. The generated powder was dissolved
in 5mL of acetonitrile 50% (vol/vol) followed by centrifugation.
The resulting supernatant is referred to as antimicrobial crude
extract (CE). The CE was analyzed using the Waters 1525 Breeze
system. The solvents were (A) HPLC-grade water with 0.1%
trifluoroacetic acid (TFA) and (B) acetonitrile, and these solvents
were applied using the following gradient: 20–60% B from 0
to 30min at a flow rate of 1.0mL/min. The resulting quantity
of Thsα, Thsβ, and Thsβ’ was quantified by weighing and the
compounds were reconstituted in distilled water (0.5 mg/mL).
Vancomycin hydrochloride was purchased from Sigma with
purity greater than 90% and was reconstituted in distilled water
(0.1mM). Purification of thuricin 4A-4 and ticin A4 was carried
out as described previously (Xin et al., 2015a,b). The purities of
thuricin 4A-4, ticin A4, Thsα, Thsβ, and Thsβ’ were determined
by HPLC using the above described procedure, and the values all
exceeded 90%.
The Optimal Peptide Ratio for the
Antimicrobial Effect of Thusin
The activated B. thuringiensis BMB171 cultures were subcultured
in 5mL of LB medium (5 × 105 cfu/mL) that contained varying
amounts of Thsα and Thsβ (or Thsβ’) at 28◦C with agitation at
220 rpm for 5 h. Bacterial growth was evaluated by measuring the
culture OD600.
Antimicrobial Activity Assay and
Determination of Minimal Inhibitory
Concentration (MIC) Values
The antimicrobial activity of the fermental supernatant of strain
BGSC 4BT1 and the eluate in HPLC analysis were assessed using
the agar well diffusion method as described previously (Xin
et al., 2015b). The minimal inhibitory concentration (MIC) was
assessed using the DIN-58940-8microdilutionmethod (Assadian
et al., 2011). Briefly, the test strains were cultivated overnight
and diluted to reach 5 × 105 cfu/mL. Tests were performed
FIGURE 2 | LC-MS analysis of a crude extract from a B. thuringiensis BGSC 4BT1 culture supernatant. Only three fractions (A, B, and C) corresponding to
three peaks with retention times of 18.1, 19.0, and 19.4min were active against B. thuringiensis BMB171. The complementary activity was observed between
fractions A and B as well as between fractions A and C but not between fractions B and C.
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FIGURE 3 | ESI-MS/MS spectra and proposed primary structure of Thsα (A) and Thsβ (B). Fragment ions are indicated. The putative thioether bridging rings
of Thsα and Thsβ are shown. Two of the six Ser/Thr residues are not dehydrated in mature peptides of ThsA2, but these residues could not be conclusively identified
based on the current data; these six amino acids are shown in gray. The putative thioether bridging rings of Thsβ in the dashed boxes were presumed based on the
reported class II lantibiotics which had been identified their structures.
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using 96-well microtiter plates. Each well was filled with 100µL
of serial two-fold dilutions of the antimicrobials and 100µL of
the inoculum and incubated at 37◦C for 24 h. All experiments
were performed in triplicate. The MIC was defined as the lowest
concentration of samples that could inhibit visible growth of the
tested strains.
Structural Analysis of Thsα, Thsβ, and
Thsβ’
LC-MS and LC-MS/MS were used to analyze the structures
of Thsα, Thsβ, and Thsβ’ using the Agilent 6540 ultra-high-
definition (UHD) accurate-mass quadrupole time of flight
(Q-TOF) LC-MS system. The MS operating conditions were as
follows: capillary voltage, 3500V; flow rate of drying gas, 9 L/min;
nebulizer pressure, 35 lb/in2 gauge; and temperature, 350◦C. The
scanning range of the Q-TOF was m/z 100 to 3000. MS/MS
analysis was performed on the doubly and tripled charged ions
of each peptide. The target ion fragmented by adding a voltage
varied from 20 to 80V.
Sensitivity of Antimicrobial Peptides to
Temperature and pH
To determine the sensitivities of Thsα, Thsβ, and Thsβ’ to pH,
aliquots of the bacteriocin preparations (5×MIC) were adjusted
to pH 2.0, 3.0, 7.0, 8.0, 9.0, and 10.0 with 1M NaOH or 1M
HCl solution followed by incubation at 28◦C for 2 h, and the
residual antimicrobial activity was measured after neutralizing
the sample to pH 6.0. For the thermal stability assay, aliquots of
the bacteriocin preparations (5 ×MIC) were exposed to 80, 100,
and 121◦C for 30min and used for an antimicrobial activity assay.
B. thuringiensis BMB171 was used as the indicator strain in these
two experiments.
Thsα and Thsβ Act Sequentially to Affect
the Sensitive Strain
The B. thuringiensis BMB171 cultures (OD600 ≈0.5) were diluted
10-fold, and 200µL of the diluted culture was added to 1.5mL
Eppendorf tubes that contained Thsα or Thsβ (at concentrations
of 0, 10, 30, and 60 nM). The tubes were incubated at 37◦C
for 30min prior to centrifugation at 12,000 rpm for 1min. The
supernatants were removed from each tube, and the cell pellets
were washed twice with LB broth, then resuspended in 200µL
of LB broth. Cells that had been treated with only Thsα were
added to microtiter wells that contained Thsβ, and cells that had
been exposed to only Thsβ were added to microtiter wells that
contained Thsα (at concentrations of 0, 10, 30, and 60 nM). The
microtiter plates were incubated at 28◦C andmonitored at hourly
intervals for 5 h. In addition, cells exposed to Thsα and Thsβ in
combination at a ratio of 1:1 served as a control.
Inhibition of Bacillus cereus Spore
Outgrowth
Germination assays were conducted as described previously
(Hornstra et al., 2005) with few modifications. B. cereus
ATCC14579 spores were activated by incubation at 70◦C for
15min and were then transferred into LB broth at an optical
density at 600 nm of 0.8. After adding different amounts
of antimicrobials, the germination process was followed by
monitoring the optical density at 600 nm every 10min.
Nucleotide Sequence Accession Number
The whole-genome shotgun sequencing results for B.
thuringiensis BGSC 4BT1 have been deposited in GenBank
under accession no. LILG00000000. The nucleotide sequence of
the thusin gene cluster has been deposited in GenBank under
accession no. KT454399.
RESULTS
Characterization and Identification of One
Two-Component Lanthipeptide
Biosynthetic Gene Cluster in
B. thuringiensis BGSC 4BT1
Our previous research demonstrated that B. cereus group strains
are a prolific source of novel lantibiotics, and four types of
the two-component lanthipeptide biosynthetic gene clusters that
have not yet been biochemically characterized were predicted
in the strains of this group (Xin et al., 2015b). Among these
clusters, one type of putative two-component lanthipeptide
gene cluster can be mined from the genome sequences of
B. thuringiensis BGSC 4BD1 and 4BT1, and we functionally
verified this gene cluster in strain 4BT1. This gene cluster,
∼10 kb in length, consists of eight genes, including three
structural genes (thsA1, thsA2, and thsA2′), two genes encoding a
posttranslational modification enzyme (thsM1 and thsM2), two
genes encoding an ABC transporter that could be involved in
immunity (thsEF), and one gene (thsT) encoding a transporter
(Figure 1A). Only one putative promoter was predicted in
the upstream thsA1 gene, and no terminator was found in
the DNA region of this gene cluster (Figure 1A). In addition,
three putative precursor peptides are characterized by an N-
terminal leader sequence with a conserved G (G/A) cleavage
site (Figures 1B,C). The amino acid sequence of ThsA1 (71
FIGURE 4 | Effects of the Thsα and Thsβ mixture on B. thuringiensis
BMB171 growth at varying ratios of the peptides, with different total
concentrations displayed as gray (60nM) and black (30nM) bars.
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aa) shows the highest identity with LchA1 (43.8%).(Shenkarev
et al., 2010) The sequences of ThsA2 (62 aa) and ThsA2’
(61 aa) are nearly identical (95% identity), and they are
most similar to that of LtnA2 (33.3 and 30.8%, respectively)
(Ryan et al., 1999).
Purification and Identification of Thsα,
Thsβ, and Thsβ’
The kinetics of the antimicrobial substance production assay
demonstrated that strain 4BT1 produced antimicrobials during
the exponential phase (Figure S1). The antimicrobials from
a 12 h culture of 4BT1 in LB medium (the exponential
phase of growth) were concentrated on Amberlite XAD-7
HP resin and separated by reverse-phase HPLC (RP-HPLC).
As shown in Figure 2, only three fractions corresponding to
three peaks with retention times of 18.1min, 19.0min and
19.4min were active against B. thuringiensis BMB171. Note
that complementary activity was observed between fractions
A and B as well as between fractions A and C but not
between fractions B and C. This phenomenon was similar
to that observed for a previously reported two-component
lantibiotic, lacticin 3147 (Ryan et al., 1999). Moreover, the
LC-MS data showed that the molecular mass of fraction A
was 3928.89 Da (Figure 2). The calculated molecular mass of
the predicted mature peptide of ThsA1, Thsα, was 198.74 Da
higher than the measured mass, indicating that all 11 serine
and threonine residues were dehydrated. Two compounds, B
and C, with molecular masses of 2908.45 Da and 2922.45 Da,
were detected in fractions B and C, respectively (Figure 2).
The calculated molecular masses of the predicted products
of the structural genes thsA2 and thsA2′ were 3065.52 Da
and 3051.50 Da, respectively, which were each 143.07 Da
higher than the measured masses of compounds C and B,
indicating that eight of the ten serine or threonine residues were
dehydrated.
We then used LC-MS/MS to analyze the detailed sequence
information of Thsα, Thsβ, and Thsβ’. As shown in Figure 3A
and Table S1, all marked fragment ions of compound A
corresponded to fragments of Thsα. No cleavage was observed
from Ser16 to Cys26 or from Thr27 to Cys36, indicating the
presence of an intramolecular thioether bridge (Lan and/or
MeLan). The marked fragments of compound B correspond to
the fragments of Thsβ’ (Figure S2 and Table S3), and those of
compound C correspond to the fragments of Thsβ (Figure 3B
and Table S2). The molecular mass difference of fragment ions
b5, b6, and b7 was 83.03 Da, and that of fragment ions y22
and y23 was 71.04 Da, indicating that Thr6, Thr7, and Ser10
were dehydrated (Figure 3B and Figure S2). Four of the six
residues (Ser19, Ser24, Ser27, Ser29, Thr16, and Thr23) were
also dehydrated, but we could not accurately identify these
residues based on the current data. In addition, no cleavage
was observed from Thr16 to Cys30 (Figure 3B and Figure S2),
suggesting the presence of intramolecular thioether bridges, but
we could not determine the precise structure from the current
data. Given the MS/MS analysis and the structural similarity
(thioether bridging rings) between thusin and the reported two-
component lantibiotics (Figures 1B,C), we proposed possible
Lan and MeLan bridges in Thsα, Thsβ, and Thsβ’ (Figure 3 and
Figure S2).
Thsα and Thsβ Function Optimally at a 1:1
Ratio
Before assessing the specific antimicrobial activity of thusin, the
optimal ratio of Thsα to Thsβ (or Thsβ’) that maximized the
FIGURE 5 | Comparison of the antimicrobial activities of thusin, ticin A4, thuricin 4A-4, and vancomycin.
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bioactivity was determined. The ability of mixtures containing
various amounts of Thsα and Thsβ (or Thsβ’) to inhibit
the growth of B. thuringiensis BMB171 was examined. As
shown in Figure 4, thusin is active against the indicator strain
B. thuringiensis BMB171 at nanomolar levels, and Thsα and Thsβ
exhibit maximum activity at a 1:1 ratio. The combination of
Thsα and Thsβ’ also showed the same result (data not shown).
The optimal synergy of Thsα and Thsβ (or Thsβ’) at a 1:1 ratio
is consistent with reports of other two-component lantibiotics,
such as staphylococcin C55, plantaricin W, lacticin 3147, and
haloduracin (Navaratna et al., 1998; Holo et al., 2001; Morgan
et al., 2005; Oman and Van der Donk, 2009).
The Antimicrobial Activity and Stability of
Thusin
The biological activities of the HPLC-purified Thsα, Thsβ,
and Thsβ’ against a battery of Gram-positive and Gram-
negative bacteria were measured. Thsα, Thsβ, and Thsβ’
were active against all tested Gram-positive bacteria, including
B. amyloliquefaciens, B. cereus, B. thuringiensis, B. subtilis,
B. pumilus, E. faecalis, L. monocytogenes, Staph. aureus, Staph.
Sciuri, and Strep. pneumoniae, but not against any of the tested
Gram-negative bacteria (Table 1). The antimicrobial activities
of Thsβ and Thsβ’ were essentially comparable, so we only
showed the data for Thsβ. The Thsα and Thsβ mixture at
a molar ratio of 1:1 had a 4- to 16-fold increase in efficacy
compared with the peptides used individually. Therefore, Thsα
and Thsβ could synergistically inhibit Gram-positive bacteria. In
addition, we also compared the antimicrobial activity of thusin,
thuricin 4A-4, ticin A4, and vancomycin against six species of
Gram-positive pathogens (Figure 5). The MIC determinations
revealed that thusin had higher activity against all tested
Gram positive bacterial pathogens than those of thuricin 4A-
4, ticin A4, and vancomycin. Thusin had 8-fold higher activity
against L. monocytogenes LM605, Staph. aureus CMCC 26003,
Staph. aureus ATCC 43300, Staph. aureus MRSA, Staph. sciuri
Bom1, and E. faecalis ATCC 29212 than vancomycin. Thusin
showed 16-fold higher activity against B. cereus ATCC 14579
and L. monocytogenes LM201 than vancomycin. In addition,
thusin displayed 2-fold to 16-fold higher activity against nine
tested indicator bacteria than those of thuricin 4A-4 and
ticin A4 (Figure 5). These results suggested that thusin might
be more effective at treating infections caused by Gram-
positive pathogens than thuricin 4A-4, ticin A4 and even
vancomycin.
The sensitivities of Thsα, Thsβ, and Thsβ’ to pH and
temperature were also tested. As shown in Figure 6A, Thsα,
Thsβ, and Thsβ’ were all stable under acidic conditions, but
were not stable under neutral and alkaline conditions. All
of the peptides totally lost their activity when they were
incubated at pH 10.0 for 2 h. In addition, Thsα, Thsβ, and
Thsβ’ all remained active after incubation at 80 and 100◦C for
30min (Figure 6B). Thsα retained approximately 50% of its
activity when it was autoclaved at 121◦C for 30min, but the
residual antibacterial activities of Thsβ and Thsβ’ were greatly
decreased.
FIGURE 6 | Thermal and pH stabilities of Thsα, Thsβ, and Thsβ’.
B. thuringiensis BMB171 was used as the indicator strain in these two
experiments. (A) The stabilities of Thsα, Thsβ and Thsβ’ under various pH
conditions. (B) The sensitivities of Thsα, Thsβ, and Thsβ’ to temperature.
Antimicrobial activity was assessed using the agar well diffusion method. Well
size = 6mm. All assays were repeated at least three times, and representative
results are shown.
Thsα and Thsβ Act Sequentially to Affect
Sensitive Strains
To reveal the potential roles of the individual peptides of
thusin, the peptides were sequentially added and cell growth
was examined. As indicated in Figure 7B, when the sensitive
strains were incubated with Thsα prior to incubation with Thsβ,
cell growth was inhibited. When the cells were first exposed to
Thsβ and were subsequently treated with Thsα, growth inhibition
was not observed (Figure 7C). When Thsα and Thsβ peptides
were added in combination, growth inhibition was observed
(Figure 7A).
Thusin Can Inhibit the Outgrowth of
Bacillus cereus Spores
The ability of thusin to prevent spore outgrowth was assessed.
The optical density of the samples at 600 nm indicated that
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FIGURE 7 | Sequential activity of thusin peptides against B.
thuringiensis BMB171. (A) Thsα and Thsβ simultaneously added. (B) Thsα
followed by Thsβ addition. (C) Thsβ followed by Thsα addition. Different
concentrations are displayed as black (0 nM), gray (10 nM), red (30 nM), and
blue (60 nM) lines. The means and standard deviations are presented.
thusin could inhibit the outgrowth of B. cereus spores when the
concentration reached 0.39µM (Figure 8). In addition, Thsα,
Thsβ and Thsβ’ could also inhibit the outgrowth of spores
when the concentration was greater than 6.25µM, 12.5µM and
12.5µM, respectively (data not shown). Therefore, Thsα and
Thsβ (or Thsβ’) could synergistically inhibit the outgrowth of
B. cereus spores.
DISCUSSION
The increasing incidence of drug-resistant pathogens has
prompted the pharmaceutical and scientific communities to
investigate alternatives to traditional antibiotics, such as
bacteriocins. Bacteriocins exhibit several desirable properties that
make them suitable as alternatives to traditional antibiotics: (i)
they are potent (in vitro and in vivo), (ii) they are minimally
toxic, (iii) they can be produced in situ by probiotics, and (iv)
they are amenable to bioengineering (Cotter et al., 2013). A
subgroup of bacteriocins, lantibiotics, especially two-component
lantibiotics, exhibit potent antimicrobial activity against clinically
relevant pathogens, including multidrug-resistant strains, and
they are being extensively researched as a potential new source of
antimicrobials to treat infections (Cotter et al., 2013; Dischinger
et al., 2014; Sandiford, 2014). Given the high potency and
potential clinical applications of two-component lantibiotics, this
study aimed to mine novel two-component lantibiotics that
exhibit excellent properties, especially in terms of antibacterial
activity against bacterial pathogens in the B. cereus group.
Finally, we identified and characterized one type of novel two-
component lantibiotic, the thusin gene cluster in B. thuringiensis
strain BGSC 4BT1. The mature peptides, Thsα and Thsβ (or
Thsβ’), act synergistically to potently inhibit several Gram-
positive pathogens, including B. cereus, L. monocytogenes, Staph.
aureus (MRSA), Staph. sciuri, E. faecalis, and Strep. pneumoniae.
To our knowledge, thusin is the first reported two-component
lantibiotic in the B. cereus group and has potential applications
in the pharmaceutical industry.
The optimal ratio of Thsα to Thsβ (or Thsβ’) that maximized
bioactivity was 1:1. Due to the differences in the maximum
absorption wavelengths of Thsα and Thsβ, the absorption peak
areas of Thsα, Thsβ and Thsβ’ at 220 nm differed (Figure 2),
but the number of moles of the compounds was ∼2:1:1 (data
not shown). Although the three structural genes shared one
promoter, the transcription of thsA1 likely exceeded that of thsA2
and thsA2′. Consequently, the yields of Thsα, Thsβ and Thsβ’
were close to the optimal ratio to maximize the effect on cells.
In our previous study, we identified two single-component
lantibiotics, thurisin 4A-4, and ticin from B. thuringiensis T01001
and BMB3201, respectively (Xin et al., 2015a,b). We found that
the cell-free supernatants of B. thuringiensis T01001, BMB3201,
and BGSC 4BT1 exhibited comparable antimicrobial activity
against most of the tested Gram-positive strains (data not
shown). The production of thurisin 4A-4 and ticin were both
∼1mM/L, but thusin was only 0.1 to 0.2mM/L. Comparison of
antimicrobial activity between thusin, thuricin 4A-4, and ticin A4
showed that thusin had higher activity against all tested indicator
bacteria (Figure 5). Therefore, the antimicrobials produced by
B. thuringiensis BGSC 4BT1 was less than those from two other
strains but played a comparable activity. This result indicated
that the production of two-component lantibiotics was more
effective than the production of single-component lantibiotics
based on the survival and adaptability of the producer strains
in various ecological environments. Another way, the low yield
of thusin will not be conducive to its future application, and
we will take some genetic engineering strategies to improve
the production of thusin in further research. For example,
overexpression of thusin self-protection genes in the producer
strain (Heinzmann et al., 2006).
Comparison of antibacterial activity between thusin and
vancomycin demonstrated that thusin had a higher activity
against all tested Gram-positive pathogens. The glycopeptide
antibiotic vancomycin was introduced clinically nearly 60 years
ago and has been widely used to treat severe infections due
to Gram-positive bacteria resistant to β-lactam antibiotics,
in particular the infection caused by methicillin-resistant
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FIGURE 8 | Inhibition of Bacillus cereus spore outgrowth by thusin. The
germination process of B. cereus ATCC14579 spores was monitored by
measuring the optical density at 600 nm every 10min.
S. aureus (MRSA) (Mainardi et al., 2008). However, the
emergence of vancomycin-resistant enterococci (VRE) and
vancomycin-resistant staphylococci attenuated its application in
recent years (Leclercq et al., 1988; Uttley et al., 1988; Centers
for Disease Control and Prevention, 1997; Chang et al., 2003;
Courvalin, 2006). In addition, thusin also showed higher activity
against all tested indicator bacteria than thuricin A4 and Ticin
A4. These results suggested that thusin had obvious advantages
in terms of antimicrobial activity, and also indicated the potential
for its use as an alternative to conventional antibiotics against the
infections caused by Gram-positive pathogens.
Lipid II has been identified as the target molecule of a
number of lantibiotics, such as mersacidin. The C ring of
mersacidin can bind to lipid II and inhibit transglycosylation
in a Ca2+-dependent manner, and this structure is conserved
in other class II lantibiotics (Brötz et al., 1998; Hsu et al.,
2003; Knerr and Van der Donk, 2012), including Thsα. Recent
studies have revealed the mode of action of the two-component
lantibiotics lacticin 3147 and haloduracin: the α-peptide first
interacts specifically with lipid II and the lipid II: α-peptide
complex is then able to recruit the β-peptide to form an
active three-component complex and subsequently inhibit cell
wall biosynthesis to form small pores in the cell membrane
(Morgan et al., 2005; Wiedemann et al., 2006; Oman and
Van der Donk, 2009). We found that Thsα and Thsβ acted
sequentially to affect the sensitive strain B. thuringiensis BMB171,
and this phenomenon was identical to that observed for the
two-component lantibiotics lacticin 3147 and haloduracin. We
speculated that Thsα binds the cell wall precursor lipid II, and the
lipid II:Thsα complex is required for Thsβ to exert its synergistic
effect to inhibit cell wall biosynthesis and form pores in the cell
membrane. We will test this hypothesis in future studies.
B. cereus is a human pathogen that causes diarrheal or
emetic-type illnesses (Ramarao and Sanchis, 2013). Its highly
resistant spores can survive in food processing treatments and
can be present in final products, where they may lead to food
spoilage and food-borne illness (Warda et al., 2015). Previous
studies have shown that some lantibiotics are able to inhibit the
outgrowth of Bacillus spores (Liu and Hansen, 1993; Oman and
Van der Donk, 2009; Gut et al., 2011). In this study, we revealed
that the components of thusin synergistically prevented the
outgrowth of B. cereus spores. To date, only the molecular basis
by which nisin inhibits spore outgrowth has been extensively
studied. Specifically, nisin utilizes lipid II as the germinated
spore target during outgrowth inhibition and causes membrane
disruption (Liu and Hansen, 1993; Gut et al., 2011). The
mechanism by which two-component lantibiotics such as thusin
prevent the outgrowth of B. cereus spores may differ from that
of the single-component lantibiotic nisin; we will investigate
this mechanism in future studies. However, the ability of thusin
to inhibit the outgrowth of B. cereus spores demonstrates its
potential application in the food industry.
Finally, we have to emphasize that the systematic safety testing
of thusin and its antimicrobial activity in vivo are crucial for its
successful application as a new drug or food additive. We have
determined that thusin (>1 mg/mL) had no hemolytic activity
(data not shown), and more detailed testing will be performed to
assess the feasibility of its application in further study.
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